MedTrace Logo

Steroids After Laser Trabeculoplasty for Glaucoma

NCT00981435 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2019-08-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the choice of post-operative eye drop administered after selective laser trabeculoplasty (SLT) for glaucoma affects the efficacy in lowering intraocular pressure (IOP).

Conditions

Interventions

DRUG

Prednisolone 1%

Prednisolone 1% to lasered eye 4 times/day for 4.5 days

DRUG

Ketorolac

Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days

DRUG

Artificial Tears

Artificial saline tears to lasered eye 4 times/day for 4.5 days

Sponsors & Collaborators

  • Bascom Palmer Eye Institute

    collaborator OTHER

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Jeffrey L Goldberg, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981435 on ClinicalTrials.gov